一个MMR熟练的结肠癌的子集对新辅助免疫疗法做出了反应
Eleonora Piumatti1,2, Giovanni Germano2,3, Pietro Paolo Vitiello1,2
1Department of Oncology, Molecular Biotechnology Center, University of Torino, Turin, Italy.
Molecular oncology
|December 1, 2025
概括
新辅助免疫疗法对不匹配修复性结直肠癌 (pMMR CRC) 有望,在早期患者中达到26%的应答率. 以生物标志物为指导的治疗可能会改善病理反应,这需要进一步的临床评估.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- 不匹配修复能力 (pMMR) 的结直肠癌 (CRC) 在历史上没有对免疫检查点阻塞 (ICB) 的反应.
- 新出现的证据表明,新辅助免疫疗法可能通过减少术后复发而有利于pMMR CRC.
研究的目的:
- 评估新辅助免疫治疗在早期pMMR结肠癌 (CC) 的疗效.
- 在pMMR中识别免疫治疗反应和不反应的分子决定因素CC.
主要方法:
- 该NICHE-2试验评估了新辅助免疫疗法在早期的pMMRCC患者.
- 分子分析调查了瘤特征,免疫细胞透和响应者与非响应者的信号通路.
- 在手术后监测循环瘤DNA (ctDNA) 水平.
主要成果:
- 在接受新辅助免疫治疗的早期pMMRCC患者中观察到26%的应答率.
- 响应者表现出更高的染色体不稳定性 (CIN),TP53突变和增殖特征,CD8+ T细胞透率增加.
- 没有反应的患者表现出代谢/流体重编程,TGF-β信号传递和免疫排除.
- ctDNA清除与病理反应和无病生存率相关.
结论:
- 新辅助免疫疗法可以在早期的pMMR CC.中实现病理反应.
- 生物标志物导向免疫疗法代表了对pMMRCC的潜在策略,尽管临床相关性需要进一步研究.
- 分子签名区分了响应者和非响应者,为治疗机制提供了洞察力.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
628
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
2.6K
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
